STABILITY
- 15,500 participants
- 12 sites in New Zealand
- 39 participating countries
STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY
A Multi-centre, Randomised, Double-Blind, Placebo-controlled, Event-driven Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).
This is a phase III randomized, multi-centre, placebo-controlled, double-blind, parallel group, event-driven study involving an investigational drug darapladib (SB-480848). This study will compare the chronic effects of darapladib versus placebo when added to the standard of care, on the incidence of major adverse cardiovascular events (MACE) in high risk patients with chronic Coronary Heart Disease (CHD).